Floatz logo

Alemtuzumab

Common Variable Immunodeficiency

Paul Szabolcsmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Common Variable Immunodeficiency cohort.

Asset / SponsorPhaseRating
Conestat Alfa
IMMUNOe Research Centers
Phase 4BB
Thiotepa
University of Florida
Phase 2BB
Human Immunoglobulins
Grifols Therapeutics LLC
Phase 3B
Fludarabine
Paul Szabolcs
Phase 2CCC
Melphalan
Paul Szabolcs
Phase 2CCC

View all 18 →

Same molecule, other indications

Alemtuzumab is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative · Phase 2
71 / 100
View asset →
chronic myeloid leukemiaActive
BB
Indicative · Phase 2/3
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →